Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

Lymphoma

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.
Lymphoma
II
Oluwole, Olalekan
NCT03761056
VICCBMT18146

Hematologic Malignancy Tumor Bank

Multiple Cancer Types

Hematologic, Leukemia, Lymphoma
N/A
Mosse, Claudio
VICCHEM1217

Observation of Low-Dose Skin Electron Therapy in Patients with Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

Lymphoma

This trial collects data on response to low-dose skin electron therapy in patients with stage IB-IIIA mycosis fungoides that does not respond to treatment (refractory) or has come back (relapsed). Collecting data on patient's response to therapy, both in terms of changes in the skin and in terms of quality of life following treatment, may help doctors better predict response to therapy.
Lymphoma
N/A
Kirschner, Austin
NCT02702310
VICCRAD1633

A Study of ME-401 in Subjects With CLL / SLL, FL, and B-cell Non-Hodgkin's Lymphoma

Multiple Cancer Types

A Three-Arm Study of ME-401 in Subjects with Relapsed / Refractory CLL / SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL
Leukemia, Lymphoma
I
Reddy, Nishitha
NCT02914938
VICCHEM1714

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Multiple Cancer Types

This phase Ib trial studies the side effects and best dose of venetoclax and selinexor and how well they work in treating patients with high risk hematologic malignancies such as diffuse large B-cell lymphoma, multiple myeloma, or acute myeloid leukemia that have come back (recurrent) or do not respond to treatment (refractory). Venetoclax functions by inhibiting or slowing down a protein in the body called bcl-2, which is involved in slowing down the normal process by which old cells in the body are cleared (called apoptosis). Selinexor functions by trapping “tumor suppressing proteins” within the cell and causing the cancer cells to die or stop growing. This study examines the effects, if any, of selinexor and venetoclax on high risk hematologic malignancies and on the body, including any side-effects.
Hematologic, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Phase I
I
Byrne, Michael
NCT03955783
VICCHEM1755

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed / Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma

This study will enroll approximately 160 adult subjects who have relapsed or refractory (r / r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the subjects own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.
Lymphoma
II
Oluwole, Olalekan
NCT03105336
VICCBMT1844

ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Lymphoma

This is the study of the PI3K? inhibitor ME-401 in subjects with relapsed / refractory follicular lymphoma after failure of at least 2 prior lines of systemic therapy
Lymphoma
II
Reddy, Nishitha
NCT03768505
VICCPCL1913

Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Lymphoma

This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Immunotherapy with rituximab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient’s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.
Lymphoma
III
Dholaria, Bhagirathbhai
NCT03267433
ECOGBMTEA4151

A Computerized Program (Neuroplasticity-Based Cognitive Remediation) for the Treatment of Chemotherapy Related Cognitive Impairment in Patients with Breast, Colon, Lymphoma, or Ovarian Cancer

Multiple Cancer Types

This trial studies how well a computerized program called neuroplasticity-based cognitive remediation works for the treatment of chemotherapy related cognitive impairment in patients with breast, colon, lymphoma, or ovarian cancer. There are few if any treatments shown to be effective in improving thinking and functioning in patients with attention and memory problems related to cancer treatment. This may leave patients vulnerable to loss of independence and functioning, and to developing depressive symptoms. Neuroplasticity-based cognitive remediation may help to improve thinking, functioning, and depressive symptoms in patients with breast, colon, lymphoma, or ovarian cancer.
Breast, Colon, Lymphoma, Ovarian
N/A
Newhouse, Paul
NCT04230863
VICCSUPP1936

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: